About Neuroplast
Neuroplast is a company based in Geleen (Netherlands) founded in 2014. Neuroplast has raised $15.83 million across 4 funding rounds from investors including Brightlands, European Union and Lumana Invest. Neuroplast offers products and services including Neuro-Cells Therapy and Pipeline Services. Neuroplast operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Geleen, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neuroplast B.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.83 M (USD)
in 4 rounds
-
Latest Funding Round
$187.5 K (USD), Grant
Jan 01, 2023
-
Investors
Brightlands
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Neuroplast
Neuroplast offers a comprehensive portfolio of products and services, including Neuro-Cells Therapy and Pipeline Services.
Develops therapies for neurodegenerative diseases via clinical trials and research.
Provides preclinical and clinical trial support for stem cell applications.
Funding Insights of Neuroplast
Neuroplast has successfully raised a total of $15.83M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $187.5 thousand completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neuroplast
Neuroplast has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Brightlands, European Union and Lumana Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
LIOF is engaged in supporting innovative entrepreneurs in Limburg.
|
Locked | Locked | Locked | |
|
Brightlands Venture Partners is focused on venture capital investments.
|
Locked | Locked | Locked |
Investor details for Neuroplast
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neuroplast
Investment portfolio details for Neuroplast
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neuroplast
Detailed financials for Neuroplast
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neuroplast Comparisons
Peer comparison for Neuroplast
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neuroplast
Neuroplast operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Neuroplast
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neuroplast
Complete news archive for Neuroplast
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neuroplast
Neuroplast was founded in 2014 and raised its 1st funding round 6 years after it was founded.
Neuroplast is headquartered in Geleen, Netherlands. It is registered at Geleen, Limburg, Netherlands.
Johannes de Munter is the current CEO of Neuroplast.
Neuroplast is a funded company, having raised a total of $15.83M across 4 funding rounds to date.
Neuroplast was founded in 2014 in Geleen, Netherlands, within the biotechnology sector. Neuro-regenerative medicines are developed by the company for patients affected by nervous system damage. Operations involve research and production of autologous stem cell treatments. The lead product, Neuro-Cells, is utilized to address irreversible nerve injuries and reduce their long-term effects. Focus is placed on therapeutic advancements in neurology.
Neuroplast's top competitors include Jazz Pharmaceuticals, Biohaven Pharmaceutical and Sana Biotechnology.
Neuroplast offers Neuro-Cells Therapy and Pipeline Services.
Neuroplast has 5 investors. Key investors include Brightlands, European Union, Lumana Invest, LIOF, and Brightlands Venture Partners.